Open AccessSilymarin improves glycemic control through reduction of insulin resistance in newly diagnosed patients of type 2 diabetes mellitus.
Author(s) -
Aisha Memon,
Shomail Saeed Siddiqui,
Muhammad Atif Ata,
Kashif Rasheed Shaikh,
Umair Ali Soomro,
Shumaila Shaikh
Publication year - 2022
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2022.29.03.6477
Subject(s) - medicine , glycated hemoglobin , glycemic , insulin resistance , type 2 diabetes mellitus , insulin , diabetes mellitus , hypoglycemia , type 2 diabetes , confidence interval , gastroenterology , endocrinology , hemoglobin
Objective: To study, analyse and compare the effects of Silymarin on glycemic control and insulin resistance in newly diagnosed type 2 diaebtes mellitus (T2DM) subjects. Study Design: Observational study. Setting: Suleman Roshan Medical College Hospital. Period: March 2019 to February 2020. Material & Methods: A sample of 200 newly diagnosed cases of T2DM were recruited accroding to inclusion criteria selected by non-probability convenient sampling. Subjects were divided into 2 groups; OHA- oral hypoglycemia agent and OHA+ Sillymarin (200 mg). Baseline fasting (FBG) and random blood glucose (RBG), glycated HbA1 (A1C), fasting insulin (FI) and insulin resitance (HOMA-IR) were detected. Silymarin therapy was continued for 3 months. Study variables were analysed after 3 months. Data was analyzed on SPSS (ver.19) at 95% confidence interval (P≤0.05) considered statistially significant. Results: Age of diabetics taking oral hypoglycemic agents (OHA) and diaebtic taking OHA+ Silymarin supplementation was noted as 50.3±13.3 49.9±14.5 years (P=0.91). 3 months Silymarin supplementation improves the fasting blood glucose, random blood glucose, glycated hemoglobin A1 (A1C), fasting insulin and insulin resistance (HOMA-IR) (P=0.0001). Conclusion: Silymarin improves blood glucose levels in type 2 diabetics that is mediated through reduction of insulin resistance.